PHOENYCS FLYNCT06617325
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 51 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 242 → 245 locations
- Minor Site details revised at 4 of 242 sites
- Notable Eligibility criteria expanded, about 18 words
- Secondary endpoints: details revised at 11 of 14 entries
- Study sites revised (242)
- Minor Trial sites expanded: 238 → 242 locationsv48
- Minor Study sites: 236 to 238v47
- Minor Trial sites expanded: 233 → 236 locationsv46
- Minor Study sites: 231 to 233v45
- Minor Study sites: 230 to 231v44
- Minor Site details revised at 3 of 230 sitesv43
- Minor Study sites: 229 to 230v42
- Minor Study sites: 227 to 229v41
- Minor Study sites: 225 to 227v40
- Minor Trial sites expanded: 219 → 225 locationsv39
- Minor Trial sites expanded: 214 → 219 locationsv38
- Minor Study sites: 204 to 214v37
- Minor Study sites: 202 to 204v36
- Minor Study sites: 198 to 202v35
- Minor Secondary endpoints revised (14)v34
- Notable Eligibility criteria expanded, about 6 wordsv33
- Notable Eligibility criteria shortened, about 32 words
- Secondary endpoints: 15 to 14
- Minor Study sites: 196 to 198v31
- Minor Study sites: 185 to 196v30
- Minor Study sites: 181 to 185v29
- Minor Study sites: 177 to 181v28
- Minor Study sites: 174 to 177v27
- Minor Study sites: 167 to 174v26
- Minor Study sites: 163 to 167v25
- Minor Study sites: 164 to 163v24
- Notable Primary and study completion dates: Sep 15, 2027 to May 31, 2028
- Study sites: 159 to 164
- Minor Study sites: 155 to 159v22
- Minor Study sites: 149 to 155v21
- Minor Study sites: 142 to 149v20
- Minor Study sites: 140 to 142v19
- Minor Study sites: 133 to 140v18
- Minor Study sites: 132 to 133v17
- Minor Study sites: 129 to 132v16
- Minor Study sites: 128 to 129v15
- Minor Study sites: 122 to 128v14
- Minor Study sites: 119 to 122v13
- Minor Study sites: 114 to 119v12
- Notable Primary and study completion dates: Mar 2, 2027 to Sep 15, 2027v11
- Minor Study sites: 107 to 114v10
- Minor Study sites: 100 to 107v9
- Minor Study sites: 95 to 100v7
- Minor Study sites: 89 to 95v6
- Minor Study sites: 78 to 89v5
- Minor Study sites: 62 to 78v4
- Minor Study sites: 1 to 62v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Oct 16, 2024 to Nov 21, 2024
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48
Timeframe: Week 48
Secondary (14)
Achievement of SRI 4 response at Week 48
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48
Achievement of LLDAS at Week 40 and maintaining LLDAS at Weeks 44 and 48
Change from Baseline to Week 48 in the FATIGUE-PRO Total score
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at Baseline to ≤7.5mg/day at Week 36 and maintained through Week 48
Show 9 moreShow less
Achievement of BILAG 2004 improvement without worsening at Week 48
Change from Baseline in PGA at Week 48
Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flare-free) through Week 48
Change from Baseline in SLEDAI-2K at Week 48
Change from Baseline in FACIT-Fatigue score at Week 48
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
Percentage of participants with serious treatment-emergent adverse events during the study
Percentage of participants with treatment-emergent adverse events of special interest during the study
Percentage of participants with treatment-emergent adverse events of special monitoring during the study
Arms and interventions
Dapirolizumab pegolExperimental
Study participants will receive dapriolizumab pegol throughout the Treatment Period.
PlaceboPlacebo comparator
Study participants will receive placebo throughout the Treatment Period.
Drugs: DZP
Other: Placebo
Sites
245 sites in 23 countries
United States 63, China 36, Japan 31, Spain 15, Germany 14, Italy 13, Poland 11, Taiwan 8, Argentina 7, United Kingdom 7, South Korea 6, Denmark 4, Greece 4, Serbia 4, Canada 3, France 3, Mexico 3, Netherlands 3, Peru 3, Puerto Rico 3, Belgium 2, Chile 1, United Arab Emirates 1